Literature DB >> 26594828

Home-Based Screening for Biliary Atresia Using Infant Stool Color Cards in Canada: Quebec Feasibility Study.

Véronique Morinville1, Najma Ahmed, Cindy Ibberson, Lajos Kovacs, Janusz Kaczorowski, Stirling Bryan, Jean-Paul Collet, Richard Schreiber.   

Abstract

OBJECTIVES: Biliary atresia (BA) is a leading cause of liver failure and liver transplantation in pediatrics. BA manifests by 3 weeks of life with jaundice and pale stools. Delayed diagnosis and surgical intervention with Kasai portoenterostomy after 3 months of age is significantly associated with poor prognosis for native liver survival. A national Taiwan infant stool color card (SCC) screening program has entirely eliminated late Kasai portoenterostomy >90 days of age and improved native liver survival. A recent large-scale prospective cohort study in British Columbia, Canada, indicated that distribution of SCC on the maternity ward was feasible, led to high utilization rate, and was cost-effective. The aim of the present study was to assess the generalizability of this screening strategy in another Canadian jurisdiction with a different sociodemographic profile.
METHODS: An SCC was distributed to families of newborns discharged at St Mary's Hospital Center, Montreal, Quebec. Families were instructed to monitor their infant's stool color for 21 days and then complete and mail the SCC to the study center. Phone surveys to families who did not return cards were used to estimate total card utilization rate.
RESULTS: Two thousand two hundred forty-six infants were eligible for inclusion; 99.9% were enrolled. Mail SCC return rate was 63.3%. No cases of BA were identified. All of the 118 families who completed the phone survey reported that they had utilized the SCC. Conservative and optimistic estimates for total card utilization rates were 82% and 100%, respectively.
CONCLUSIONS: The high enrollment and utilization rates in this screening study strongly support the feasibility of implementing a Canadian SCC screening program to improve outcomes of children with BA.

Entities:  

Mesh:

Year:  2016        PMID: 26594828     DOI: 10.1097/MPG.0000000000001042

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  7 in total

1.  Clinical practices among healthcare professionals concerning neonatal jaundice and pale stools.

Authors:  Ermelinda Santos Silva; Helena Moreira Silva; Lia Azevedo Lijnzaat; Cláudia Melo; Elísio Costa; Esmeralda Martins; Ana Isabel Lopes
Journal:  Eur J Pediatr       Date:  2017-01-12       Impact factor: 3.183

2.  Screening for biliary atresia: it's in the cards.

Authors:  Richard A Schreiber; Alison Butler
Journal:  Can Fam Physician       Date:  2017-06       Impact factor: 3.275

Review 3.  Screening for biliary atresia.

Authors:  Akira Matsui
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

Review 4.  Biliary atresia: unity in diversity.

Authors:  Claus Petersen
Journal:  Pediatr Surg Int       Date:  2017-10-05       Impact factor: 1.827

5.  Biliary Atresia in 2021: Epidemiology, Screening and Public Policy.

Authors:  Richard A Schreiber; Sanjiv Harpavat; Jan B F Hulscher; Barbara E Wildhaber
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

6.  Infant Stool Color Card Screening Helps Reduce the Hospitalization Rate and Mortality of Biliary Atresia: A 14-Year Nationwide Cohort Study in Taiwan.

Authors:  Min Lee; Solomon Chih-Cheng Chen; Hsin-Yi Yang; Jui-Hua Huang; Chun-Yan Yeung; Hung-Chang Lee
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

7.  Design and validation of a noninvasive diagnostic criteria for biliary atresia in infants based on the STROBE compliant.

Authors:  Xiaoguai Liu; Xiaokang Peng; Yanxia Huang; Chang Shu; Pan Liu; Weike Xie; Shuangsuo Dang
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.